2015•MD Conference ExpressRequires access

VT-1161 Emerges as Potential Treatment for Acute Vulvovaginal Candidiasis

Reuben M. Buckley, Stephen Brand

Abstract

The novel agent VT-1161 is safe and as effective as fluconazole for treating acute vulvovaginal candidiasis infections. Furthermore, it is more effective than fluconazole for preventing recurrent vulvovaginal candidiasis infections, particularly at its mid- and high doses, according to results from a phase 2 dose-ranging study. VT-1161 is now being evaluated in patients with recurrent vulvovaginal candidiasis in the REVIVE trial.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Vulvovaginal Candidiasis, Fluconazole, Medicine, Invasive candidiasis, Dermatology, Antifungal, Intensive care medicine, Internal medicine